| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 |
|
Medicine details |
|
| Medicine name | remdesivir (Veklury®) |
| Formulation | 100 mg concentrate for solution for infusion |
| Reference number | 4600 |
| Indication | Treatment of coronavirus disease 2019 (COVID-19) in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring supplemental oxygen |
| Company | Gilead Sciences Ltd |
| BNF chapter | Infections |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/08/2020 |
| NICE guidance | TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 |